Publications scientifiques Bordet

Publications scientifiques Bordet

  • Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

  • Auteurs Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N
  • Auteurs (entité) AWADA AHMAD HUSSEIN
  • Revue J Immunother Cancer
  • Date de publication 2025-05
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
  • Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

  • Auteurs Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N
  • Auteurs (entité) DEBIEN VERONIQUE
  • Revue J Immunother Cancer
  • Date de publication 2025-05
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) DEBIEN VERONIQUE
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) DE AZAMBUJA EVANDRO
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) AGOSTINETTO ELISA
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) MOREAU MICHEL
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) PICCART MARTINE
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasmus

Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet